Overview

Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and efficacy of FK614 in type 2 diabetic subjects receiving sulfonylurea (SU) monotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Astellas Pharma US, Inc.